Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification

By Ken Rubenstein, PhD

SURVEY QUESTIONS

1. Please identify your type of organization (type of organization).
 
2. Please further identify your organization (pharmaceutical, biotech by sales volume).
 
3. Does your organization discover, develop, or in-license disease-related biomarkers?
 
For pharmaceutical, biotech respondents
 
4. Please identify your position.
 
5. Does your work involve 1 or more of the following stages or functions? Prediscovery, Discovery, Preclinical, Early-stage development, Late-stage development, Project management, Other.
 
6. Is your work involved with 1 or more of the following areas? Translational medicine, Biomarker discovery, Biomarker validation, Biomarker detection, No direct relation to biomarkers, Other.
 
7. What types of biomarkers is your company involved with?
 
8. What is your organization’s view toward collaborative biomarker development?
 
9. What is your organization’s experience with novel disease-related biomarkers?
 
10. Has your organization in-licensed or acquired a novel disease-related biomarker in the past 5 years?
 
11. Is your organization currently working toward discovering or developing disease-related biomarkers?
 
12. By what means is the discovery or development being done?
 
13. What technologies are you using to discover biomarkers?
 
14. In what therapeutic areas is your organization focusing its disease-related biomarker work?

15. Please further identify yourself (biomarker, diagnostic by sales volume)

16. Does your organization discover, develop, or employ disease-related biomarkers, as opposed to mechanism-of-action, pharmacokinetic, or toxicity-related biomarkers?

17. If your organization is not involved in discovery or development, or in-licensing, of disease-related biomarkers, please clarify the reasons.

18. Are you directly or indirectly involved in the discovery, development, or use of disease-related biomarkers?

For biomarker, diagnostic respondents
 
19. Please identify your position.

20. Is your organization currently involved in the discovery or development of novel disease-related biomarkers?

21. Has your organization in-licensed 1 or more disease-related biomarkers in the past 5 years?

22. If you answered yes to either of the 2 previous questions, what therapeutic areas are involved?

23. How does your organization plan to seek marketing approval of your biomarker?

For all respondents
 
24. What do you expect for your organization’s budget for disease-related biomarker work for fiscal 2007?

25. What do you expect for your company’s budget for disease-related biomarker work over the next 3 years?